keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) 是 CXCR4 的拮抗剂,IC50 为 ~1 nM。它通过改变 miR-15a/16-1 表达下调 ERK、BCL-2、MCL-1 和 cyclin-D1 来诱导 AML 原始细胞凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,130 | 现货 | ||
5 mg | ¥ 3,190 | 现货 | ||
10 mg | ¥ 4,670 | 现货 | ||
25 mg | ¥ 7,380 | 现货 | ||
50 mg | ¥ 9,980 | 现货 | ||
100 mg | ¥ 13,300 | 现货 |
产品描述 | Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ~1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. |
靶点活性 | CXCR4:~1 nM |
体外活性 | Treatment with BL-8040 induces the robust mobilization of AML blasts from the BM. In addition, AML cells exposed to BL-8040 undergoes differentiation. BL-8040 induces the apoptosis of AML cells in vitro, which is mediated by the up-regulation of miR-15a/miR-16-1, resulting in down-regulation of the target genes BCL-2, MCL-1 and cyclin-D1. Overexpression of miR-15a/miR-16-1 directly induces leukemic cell death. BL-8040-induced apoptosis is also mediated by the inhibition of survival signals via the AKT/ERK pathways. |
体内活性 | BL-8040 also synergizes with FLT3 inhibitors to induce AML cell death. Importantly, this combined treatment prolongs the survival of tumor-bearing mice and reduces minimal residual disease in vivo. |
别名 | TF 14016 TFA, BKT140 TFA, BL-8040 TFA, T140 TFA |
分子量 | 2273.54 |
分子式 | C99H145F4N33O21S2 |
CAS No. | T14665L |
keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 100 mg/mL (46.31 mM), Sonication is recommended.
DMSO: 100 mg/mL (46.31 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 0.4398 mL | 2.1992 mL | 4.3984 mL | 10.9961 mL |
5 mM | 0.088 mL | 0.4398 mL | 0.8797 mL | 2.1992 mL | |
10 mM | 0.044 mL | 0.2199 mL | 0.4398 mL | 1.0996 mL | |
20 mM | 0.022 mL | 0.11 mL | 0.2199 mL | 0.5498 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Motixafortide TFA(664334-36-5,Free) T14665L Autophagy GPCR/G Protein Immunology/Inflammation CXCR TF 14016 TFA BKT140 TFA Motixafortide TFA(664334 36 5,Free) BL-8040 TFA T140 TFA Motixafortide TFA(664334365,Free) Inhibitor inhibitor inhibit